Abstract:Background: To investigate the benefits and cost effectiveness of NIPT as primary or contingent strategies within high risk population, in accordance with increasing advanced maternal age (AMA) and NIPT rapid application.Methods: A theoretical model involving 1,000,000 single pregnancies was established. NIPT together with or without traditional triple serum screening constitutes five screening scenarios. All related parameters were referred to publication or on-site verification. Strategy 1, NIPT is primarily offered to all pregnant women. Strategy 2, NIPT is offered to all pregnancies with risks higher than 1:300 (Strategy 2-1) or 1:1000 (Strategy 2-2) after triple serum screening. Strategy 3 is stratified based on maternal age in which 1) for age 40 and more, prenatal diagnosis is directly offered, 2) for population of maternal age for 35~39, primary NIPT is introduced, 3) if younger than 35y, contingent strategy with risk higher than 1:300 (Strategy 3-1) or 1:1000 (Strategy 3-2) as the indication for NIPT. The primary outcome is incremental cost analysis on baseline and alterative assumptions. The second outcomes are total cost, cost-effect and cost-benefit analysis. The strategy is defined as "cost-effective" if the incremental cost is less than 0.16million US$, needed for raising one T21 livebirth or the benefit-to-cost ratio is above 1.Findings: With the advantage of lower false positive rate of NIPT, anticipated prenatal diagnosis are greatly reduced. In cost-effectiveness analysis, strategy 2-1 costs least with 112.9million US$ in total, 33.4 thousand US$ in cost-effect analysis and ratioed as 3.53 in cost-benefit analysis. Setting 2-1 as baseline, incremental costs of strategy 1, 3-2, 2-2 and 3-1 are 0.67million US$, 0.25million US$, 0.22million US$ and 0.17million US$, which are all more than costs for raising one visible T21. In sensitivity analysis of age proportion, when AMA account for more than 15.5% in population, incremental costs of strategy 3-1 are lower than 0.16million US$. All strategies are considered as "appropriate" if NIPT costs less than 106 US$. When it's less than 309 US$, the incremental cost of strategy 3-1 is least and lower than 0.16million US$. Strategy 1 needs least money when it's lower than 47 US$.Interpretation: Strategy 2-1 is optimal in cost-effectiveness analysis. AMA proportion and NIPT costs are two important factors. Strategy 3-1 is more prominent as AMA increases. Strategy 1 is the most effective and cost-effectiveness method under an affordable price.Funding: National Key Technologies R&D program of China (2016YFC1000303).Declaration of Interest: The authors have no conflict of interests.Ethical Approval: This study was exempted from ethics committee approval for the pure theoretical model involving 1,000,000 single pregnant women in China.

Maternal age-specific risk for trisomy 21 based on the clinical performance of NIPT and empirically derived NIPT age-specific positive and negative predictive values in Japan

Predictive Significance of Risk Value in Prenatal Screening for Fetal Trisomy 18

Analysis of the results of non-invasive prenatal testing (NIPT) in 545 pregnant women in advanced maternal age

Clinical application of noninvasive prenatal testing for the detection of trisomies 21, 18, and 13: a hospital experience.

Efficiency of Non-invasive Prenatal Screening in Pregnant Women at Advanced Maternal Age

Noninvasive Prenatal Testing of Trisomies 21 and 18 by Massively Parallel Sequencing of Maternal Plasma DNA in Twin Pregnancies.

Detection of Cell-Free Fetal DNA in Maternal Plasma for Noninvasive Prenatal Screening of Fetal Chromosomal Aneuploidies in Women of Advanced Maternal Age

Non-invasive Prenatal Testing for Trisomies 21, 18 and 13: Clinical Experience from 146,958 Pregnancies.

[Re-evaluation of indications for prenatal diagnosis of advanced pregnant women under the new screening regime]

[Analysis of the results of chromosomal trisomies 21, 18 and 13 screening among 40 628 women by non-invasive prenatal testing]

Association of maternal risk factors with fetal aneuploidy and the accuracy of prenatal aneuploidy screening: a correlation analysis based on 12,186 karyotype reports

Study on the Clinical Value of Noninvasive Prenatal Testing in Screening the Chromosomal Abnormalities of the Fetus in the Elderly Pregnant Women

Non-invasive prenatal testing for the diagnosis of congenital abnormalities: Insights from a large multicenter study in southern China

[Prenatal diagnosis and outcome of pregnancy for women with high risks by screening of fetal free DNA from peripheral blood samples]

Non-invasive prenatal testing for the detection of trisomy 13, 18, and 21 and sex chromosome aneuploidies in 68,763 cases

Clinical Efficiency of Non-invasive Prenatal Screening for Common Trisomies in Low-Risk and Twin Pregnancies

[Non-Invasive Prenatal Testing:Results in 3733 Cases of Twin Pregnancy and Association With Factors Such as Age]

The Application of NIPT Using Combinatorial Probe-Anchor Synthesis to Identify Sex Chromosomal Aneuploidies (scas) in a Cohort of 570 Pregnancies

Noninvasive Prenatal Testing (NIPT) in Twin Pregnancies with Treatment of Assisted Reproductive Techniques (ART) in a Single Center.

A Cost-Effectiveness Analysis of Different Screening Strategies Involving Noninvasive Prenatal Testing for Trisomy 21

Evidence of compliance with and effectiveness of guidelines for noninvasive prenatal testing in China: a retrospective study of 189,809 cases